Pharmacy costs of specialty medications for plaque psoriasis in the United States - 13/12/18
Doi : 10.1016/j.jaad.2018.04.019
Eric J. Yang, BS a, b, ⁎ 
, Kristen M. Beck, MD a, Sahil Sekhon, MD a, Tina Bhutani, MD a
, Kristen M. Beck, MD a, Sahil Sekhon, MD a, Tina Bhutani, MD a a Department of Dermatology, University of California San Francisco, San Francisco, California
b Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois
∗Correspondence to: Eric J. Yang, BS, University of California San Francisco Psoriasis and Skin Treatment Center, 515 Spruce St, San Francisco, CA, 94118University of California San Francisco Psoriasis and Skin Treatment Center515 Spruce StSan FranciscoCA94118
| Funding sources: None. |
|
| Disclosure: Dr Bhutani is an investigator for AbbVie, Janssen, Merck, Eli Lilly and Company, and Strata Skin Sciences. Mr Yang, Dr Beck, and Dr Sekhon have no conflicts of interest to disclose. |
|
| Abstracts of this work were previously presented at Maui Derm for Dermatologists in Maui, Hawaii, January 28-February 1, 2018, and the 42nd Hawaii Dermatology Seminar in Kauai, Hawaii, February 4-9, 2018. |
|
| Reprints not available from the authors. |
© 2018
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 80 - N° 1
P. 274-275 - janvier 2019 Retour au numéro
Article précédent
- Survival of patients with early invasive melanoma down-staged under the new eighth edition of the American Joint Committee on Cancer staging system
- Lena A. von Schuckmann, Maria Celia B. Hughes, Rebecca Lee, Paul Lorigan, Kiarash Khosrotehrani, B. Mark Smithers, Adele C. Green
- Analysis of national skin cancer expenditures in the United States Medicare population, 2013
- Emily Stamell Ruiz, Frederick C. Morgan, Corwin M. Zigler, Robert J. Besaw, Chrysalyne D. Schmults
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?